The use of selenium and vitamin E supplementation to prevent recurrence and progression of non-muscle-invasive bladder cancer - SELENIB
- Conditions
- on-muscle-invasive transitional cell carcinoma of the bladder
- Registration Number
- EUCTR2005-003021-19-GB
- Lead Sponsor
- niversity Of Birmingham
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- Not specified
- Able to give informed consent for SELENIB. - An initial diagnosis of: Histopathologically confirmed non-muscle-invasive transitional cell carcinoma (Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
• Disease characteristics – stage pT2 and above • Patients that are pregnant or breastfeeding • Patients diagnosed with HIV infection • Patients who are on immunosuppressive therapy following organ transplantion • Patients taking cyclosporin • Any condition which, in the opinion of the local investigator, might interfere with the safety of the patient or evaluation of the trial objectives.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method